Outcomes of irinotecan-based chemotherapy regimens in elderly medicare patients with metastatic colorectal cancer

Board, 2007, Metastatic colorectal cancer: Current systemic treatment options, Drugs., 67, 1851, 10.2165/00003495-200767130-00004 Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial [published correction appears in Lancet. 2000;355:1372], Lancet., 355, 1041, 10.1016/S0140-6736(00)02034-1 Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer, N Engl J Med., 343, 905, 10.1056/NEJM200009283431302 Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol., 22, 23, 10.1200/JCO.2004.09.046 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med., 350, 2335, 10.1056/NEJMoa032691 Etheredge, 2009, Medicare's future: Cancer care, Health Aff (Millwood)., 28, 148, 10.1377/hlthaff.28.1.148 Mariotto, 2006, Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020, Cancer Causes Control., 17, 1215, 10.1007/s10552-006-0072-0 Warren, 2002, Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population, Med Care., 40, IV-3 Dobie, 2008, Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population, Cancer., 112, 789, 10.1002/cncr.23244 Dobie, 2006, Completion of therapy by Medicare patients with stage III colon cancer, J Natl Cancer Inst., 98, 610, 10.1093/jnci/djj159 Ayanian, 2003, Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort, J Clin Oncol., 21, 1293, 10.1200/JCO.2003.06.178 Warren, 2002, Utility of the SEER-Medicare data to identify chemotherapy use, Med Care., 40, IV-55 Schrag, 2001, Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results—Medicare, J Clin Oncol., 19, 3712, 10.1200/JCO.2001.19.17.3712 Cooper, 2000, Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment, Med Care., 38, 411, 10.1097/00005650-200004000-00008 Gross, 2008, Racial disparities in cancer therapy: Did the gap narrow between 1992 and 2002?, Cancer., 112, 900, 10.1002/cncr.23228 Temple, 2004, Use of surgery among elderly patients with stage IV colorectal cancer, J Clin Oncol., 22, 3475, 10.1200/JCO.2004.10.218 Cook, 2005, Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: An analysis of surveillance, epidemiology, and end results data, 1988 to 2000, Ann Surg Oncol., 12, 637, 10.1245/ASO.2005.06.012 Cummings, 2007, Survival after hepatic resection in metastatic colorectal cancer: A populationbased study, Cancer., 109, 718, 10.1002/cncr.22448 Cooper, 2002, Use of SEER-Medicare data for measuring cancer surgery, Med Care., 40, IV-43 Delea, 2002, The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer, Value Health., 5, 35, 10.1046/j.1524-4733.2002.51083.x Du, 2005, Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity, Cancer., 104, 913, 10.1002/cncr.21271 Klabunde, 2007, A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients, Ann Epidemiol., 17, 584, 10.1016/j.annepidem.2007.03.011 Romano, 1993, Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives, J Clin Epidemiol., 46, 1075, 10.1016/0895-4356(93)90103-8 Romano, 1993, Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives, J Clin Epidemiol., 46, 1081, 10.1016/0895-4356(93)90104-9 Baldwin, 2006, In search of the perfect comorbidity measure for use with administrative claims data: Does it exist?, Med Care., 44, 745, 10.1097/01.mlr.0000223475.70440.07 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, J Chronic Dis., 40, 373, 10.1016/0021-9681(87)90171-8 Bach, 2002, Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations, Med Care., 40, IV, 10.1097/00005650-200208001-00003 Hershman, 2006, Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer, Cancer., 107, 2581, 10.1002/cncr.22316 Punglia, 2006, Radiation therapy after mastectomy between 1991 and 1999 in elderly women: Response to clinical trial information, J Clin Oncol., 24, 3474, 10.1200/JCO.2006.05.7844 Zhang, 2007, A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model [published correction appears in ComputMethods Programs Biomed. 2008;89:313–314], Comput Methods Programs Biomed., 88, 95, 10.1016/j.cmpb.2007.07.010 Fuchs, 2007, Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study, J Clin Oncol., 25, 4779, 10.1200/JCO.2007.11.3357 Hoskins, 2008, Irinotecan pharmacogenetics: Influence of pharmacodynamic genes, Clin Cancer Res., 14, 1788, 10.1158/1078-0432.CCR-07-1472